{"id":5791,"date":"2025-02-28T21:28:39","date_gmt":"2025-02-28T18:28:39","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=5791"},"modified":"2025-02-28T21:31:40","modified_gmt":"2025-02-28T18:31:40","slug":"the-2025-acc-aha-guidelines-for-managing-acute-coronary-syndromes-acs-have-introduced-several-updates-compared-to-previous-guidelines","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/the-2025-acc-aha-guidelines-for-managing-acute-coronary-syndromes-acs-have-introduced-several-updates-compared-to-previous-guidelines\/","title":{"rendered":"The 2025 ACC\/AHA guidelines for managing acute coronary syndromes (ACS) have introduced several updates compared to previous guidelines."},"content":{"rendered":"
The 2025 ACC\/AHA guidelines for managing acute coronary syndromes (ACS) have introduced several updates compared to previous guidelines. Key differences include:<\/div>\n
<\/span>\u2022 <\/span>Dual Antiplatelet Therapy (DAPT): For ACS patients not at high bleeding risk, DAPT with aspirin and a P2Y12 inhibitor is recommended for at least 12 months. For those at higher bleeding risk, alternative strategies are suggested.<\/div>\n
<\/span>\u2022 <\/span>Lipid Management: High-intensity statin therapy is advised for all ACS patients. If LDL-C levels remain \u226570 mg\/dL (1.8 mmol\/L) despite maximally tolerated statins, adding non-statin lipid-lowering agents like ezetimibe, evolocumab, alirocumab, inclisiran, or bempedoic acid is recommended.<\/div>\n
<\/span>\u2022 <\/span>Percutaneous Coronary Intervention (PCI) Approach: The guidelines now emphasize the radial (wrist) approach over the femoral (groin) approach for PCI in ACS patients to reduce bleeding, vascular complications, and mortality.<\/div>\n
<\/span>\u2022 <\/span>Intravascular Imaging: Utilizing intravascular imaging to guide PCI procedures has been elevated to a Class 1 recommendation, reflecting its importance in improving outcomes.<\/div>\n
<\/span>\u2022 <\/span>Complete Revascularization: For patients with STEMI or non-STEMI ACS, a strategy of complete revascularization is recommended, with the method chosen based on coronary artery disease complexity and comorbidities.<\/div>\n
<\/span>\u2022 <\/span>Cardiogenic Shock Management: Prompt revascularization remains crucial. New recommendations include considering microaxial flow pumps for select patients, with careful attention to vascular access and support weaning to balance benefits and risks.<\/div>\n
<\/span>\u2022 <\/span>Secondary Prevention: Post-discharge, the guidelines recommend:<\/div>\n
<\/span>\u2022 <\/span>Referral to outpatient cardiac rehabilitation (or home-based programs if outpatient services are unavailable).<\/div>\n
<\/span>\u2022 <\/span>Conducting a fasting lipid panel 4 to 8 weeks after starting or adjusting lipid-lowering therapy to assess effectiveness and determine if additional medications are needed.<\/div>\n
<\/div>\n
These updates aim to enhance the quality of care and outcomes for ACS patients by integrating the latest evidence-based practices.<\/p>\n

Download PDF file (Guideline_for_the_Management_of_Patients)<\/span>\u00a0<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

The 2025 ACC\/AHA guidelines for managing acute coronary syndromes (ACS) have introduced several updates compared to previous guidelines. Key differences include: \u2022 Dual Antiplatelet Therapy (DAPT): For ACS patients not at high bleeding risk, DAPT with aspirin and a P2Y12 inhibitor is recommended for at least 12 months. For those at higher bleeding risk, alternative […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5791","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=5791"}],"version-history":[{"count":3,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5791\/revisions"}],"predecessor-version":[{"id":5797,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5791\/revisions\/5797"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=5791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=5791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=5791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}